Summary Slide.png (89.84 kB)

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

figure

posted on 2021-02-03, 17:20 authored by Adis journals on behalf of, Shuosha Li, Huabin Hu, Dong Ding, Youwen Zhu, Jin Huang

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-021-01627-8

Usage metrics

Read the peer-reviewed publication

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

Advances in Therapy

Keywords

Binimetinib BRAF V600E mutation Cetuximab Cost-effectiveness Encorafenib Metastatic colorectal cancer

Licence

CC BY-NC 4.0

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports